ICICI Securities Recommends Buying Thyrocare Technologies, Sets Rs 620 Target
The research report says Thyrocare delivered about 25% growth in revenue, EBITDA and PAT in Q2FY27.
The research report says Thyrocare delivered about 25% growth in revenue, EBITDA and PAT in Q2FY27.